Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
Covington offers one of the world's most active and respected life sciences litigation and investigations practices. Drawing on the expertise of Covington's pre-eminent Food, Drug and Device Regulatory Practice, our litigators have guided leading and emerging life sciences companies through the most complex and high-profile investigations and lawsuits involving pharmaceuticals, medical devices, food, beverages and cosmetics. Our experience includes every dispute that a life sciences company can encounter throughout the product lifecycle, including:
Our litigators, including seven members of the American College of Trial Lawyers, have successfully tried hundreds of jury and bench trials. We appear before national and international courts in Europe, state and federal courts and enforcement authorities throughout the U.S., and arbitral tribunals throughout the world. We also counsel clients in cross-border disputes in Europe, Asia, Africa, the Middle East, and the Americas, utilizing a trusted network of local counsel and our own distinguished team of former diplomats and advisers.
AstraZeneca in an FTC investigation and private antitrust class action litigation concerning settlements of Hatch-Waxman patent litigation involving Nexium.
Won defense verdict for Salix following two-week jury trial in New York State Court. Collaboration partner Napo alleged failures to use “commercially reasonable efforts” to bring licensed drug to market. Despite seeking $260 million and contract termination, Napo recovered nothing.
Successful defense of Pfizer in both the district court and the court of appeals on a series of claims by a relator concerning Genotropin.
Representation of Amarin in the first known reversal of an FDA denial of a 5-year period of new chemical entity (NCE) exclusivity since the enactment of the Hatch-Waxman Amendments in 1984, in connection with Amarin’s Vascepa drug for lowering triglyceride levels.
Representation of a major pharmaceutical company in its response to a Chinese government commercial bribery investigation in China.
Representation of GlaxoSmithKline in global settlement of three investigations relating to off-label promotion, safety reporting and price reporting.
Successfully defended Lilly against contract and antitrust claims brought by Amylin relating to an injectable diabetes treatment. We convinced the court to dissolve a TRO and deny a preliminary injunction, allowing Lilly to proceed with promotional activities for important medicine.
Illumina in a strategic alliance with Genomics England for a four-year project to decode 100,000 human genomes.
Represented GlaxoSmithKline (GSK) in resolving a complex criminal and civil investigation by the United States Department of Justice. The multi-faceted investigation had a broad focus, including issues relating to GSK’s sales and marketing practices for numerous products, its regulatory submissions relating to Avandia, and the company’s use of the nominal price exception under the Medicaid Rebate Program.
Assisting AbbVie in structuring and negotiating a novel collaboration with the Google-backed life sciences start-up company Calico to form a $1.5 billion to fund a program focused on aging and age-related diseases.
Representation of AstraZeneca in its strategic diabetes alliance with Bristol-Myers Squibb, including with respect to collaboration arrangements for the development and commercialization of Amylin Pharmaceuticals’ portfolio of diabetes products following BMS’s acquisition of Amylin in a deal valued at $7 billion (approximately half the cost of which was borne by AstraZeneca).
Salix Pharmaceuticals in its licensing agreement with Alfa Wasserman S.p.A., by which Salix has licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin.
February 10, 2017, Law360
Law360 selected Covington’s Life Sciences practice as a “Practice Group of the Year,” highlighting the firm’s involvement in billion-dollar transactions, success in contentious litigation, and regulatory advice on cutting-edge technology. According to Michael Labson, “What we offer and bring to complicated, complex issues is a mixture of deep subject-matter ...
January 17, 2017, Law360
Law360 selected Covington’s Product Liability practice as a “Practice Group of the Year,” profiling the team’s defense of Takata in litigation over potentially explosive airbags and Bayer Healthcare in multidistrict litigation (MDL) over Mirena IUDs, among other matters. According to Paul Schmidt, the firm’s range of work showcases its diversity of ...
November 3, 2016, FDLI Introduction to Medical Device Law and Regulation Course
June 13-14, 2016, FDLI/CDRH In-House Training: Introduction to Medical Device Law and Regulation Workshop
March 31, 2016, FDLI Hot Topics in Medical Device Law Conference
December 22, 2015
WASHINGTON, DC, December 22, 2015 - The American Lawyer has named Covington its “Litigation Department of the Year: Product Liability.” The magazine recognizes the firm for its “string of big victories in trial and appellate courts, major settlements, plus a creative strategic edge that sets it apart.”
In its profile of the firm in its January 2016 issue, The ...
September 16, 2015, FDLI/CDRH In-House Training: Introduction to Medical Device Law and Regulation Workshop
August 2015, An Extract from The European Antitrust Review 2016
June 17, 2015, Life Sciences Essentials Webinar Series
January 13, 2015
WASHINGTON, DC, January 13, 2015 — For the third consecutive year, Law360 named Covington’s life sciences practice one of the top “Life Sciences Practice Groups of the Year.” Law360 recognized Covington for its “significant litigation wins and helping clinch big deals between pharmaceutical companies.” Among the matters highlighted were Covington’s handling of ...
December 31, 2013, Covington E-Alert
March 9, 2009, Covington E-Alert
November 6, 2007
WASHINGTON, DC, November 6, 2007 — Covington & Burling LLP has won a favorable arbitration ruling for GPC Biotech AG in its dispute with Spectrum Pharmaceuticals, Inc. Yesterday, a three-arbitrator panel of the American Arbitration Association unanimously rejected all of Spectrum’s claims against GPC Biotech under their co-development and license agreement for ...
June 18, 2007
WASHINGTON, DC, June 18, 2007 — Covington & Burling LLP received 44 practice mentions and 74 individual mentions in the newly released 2007 Chambers USA guidebook. The 2007 edition of Chambers USA attempts to identify the most skilled legal practitioners throughout the country based on the qualities most valued by clients. Covington attorneys have been ...
January 11, 2006
WASHINGTON, D.C., January 11, 2006 - Covington & Burling announced today it was awarded worldwide first place firm rankings in the Life Sciences Industry and Life Sciences Regulatory categories. The Life Sciences Industry Super League and Life Sciences Regulatory Super League law firm rankings, published in the Practical Law Company's Cross-border Quarterly ...
October 3, 2002
October 3, 2002 - WASHINGTON, D.C. - Covington & Burling announced that eight attorneys have been elected to the partnership, effective October 1, 2002. New partners in Covington's Litigation Practice include Georgia Kazakis and Edward H. Rippey. Michael S. Labson is a new partner in the firm's Food and Drug and Life Sciences Practices. Erin M. Egan and Jennifer ...